ARTICLES BY C. RAJAN

• Janssen Enters New Collaborations For Cancer And Antibody Research

  12/26/2014

  Janssen Biotech has entered into a collaboration with MacroGenics to co-develop the latter’s novel cancer drug candidate, MGD011, which is designed to treat multiple B-cell malignancies. The collaboration and license agreement can net up to $700 million for MacroGenics.

• Ipsen’s Triptorelin + Tamoxifen Shows Benefits In Phase 3 Breast Cancer Trial

  12/17/2014

  French pharmaceutical company, Ipsen, has announced that the use of its ovarian suppressant, triptorelin, as adjuvant treatment in combination with cancer drug tamoxifen was capable of reducing breast cancer recurrence in a Phase 3 trial.

• Spark Therapeutics Enters Collaboration With Pfizer To Develop New Hemophilia B Therapies

  12/15/2014

  Spark Therapeutics has announced that it has entered into a global collaboration with Pfizer to develop and commercialize a potential treatment for hemophilia B, SPK-FIX, which is based on bio-engineered adeno-associated virus (AAV) vectors.

• Vaximm’s Oral Cancer Vaccine Succeeds In Phase 1 Study

  12/10/2014

  Swiss biotech firm, Vaximm AG, has announced the positive follow-on data from the first clinical trial of its novel oral T-cell vaccine, VXM01 in pancreatic cancer patients. The data from a trial extension of the Phase 1 study indicate that VXM01 triggers a strong T-cell-mediated immune response in patients.

• Meridian Life Science Wins Second SBIR II Contract For Developing Rotavirus Vaccine

  12/8/2014

  Tennessee-based life science company, Meridian Life Science (MLS), has been awarded a Small Business Innovation Research (SBIR) contract by the Centers for Disease Control and Prevention (CDC) to develop a process to manufacture a rotavirus vaccine.

• GeNeuro Partners With Servier In $455M Deal To Co-Develop MS Drug

  12/8/2014

  Geneva-based biotech firm, GeNeuro, has entered a partnership with French pharmaceutical company, Servier, to co-develop and market a novel Multiple Sclerosis (MS) treatment.

• BioMarin Acquires Prosensa For Up To $840M

  12/2/2014

  California based drug maker BioMarin Pharmaceuticals has agreed to acquire Dutch biotech company, Prosensa, for nearly $840 million in a deal that BioMarin is hoping will enable the company to win regulatory approval for a treatment for Duchenne muscular dystrophy (DMD), a rare and fatal disease.

• Ipsen To Launch New Peptide Research Lab

  11/26/2014

  French pharmaceutical company Ipsen has extended two of its strategic partnerships with academia to new levels in the past week by setting up a new peptide research lab and committing to research in medical sciences.

• Abivax Partners With Finlay Institute To Commercialize Vaccines In Emerging Markets

  11/18/2014

  French biopharmaceutical company, Abivax, has signed an agreement with vaccine maker, The Finlay Institute in Cuba, which will allow Abivax to commercialize vaccines against three major infectious diseases in the Asian and Latin American markets. 

• Dr. Reddy’s To File Two New NDAs Within A Year

  11/7/2014

  India based pharmaceutical company, Dr. Reddy’s Laboratories (DRL), announced this week that it expects to file two new drug applications (NDAs) with the US FDA within one year’s time, reports The Economic Times of India.

• Universal Flu Vaccine Ready For Pharma Licensing And Development

  11/3/2014

  Israeli biotech firm, BiondVax, has announced that its patent for the universal flu vaccine has been approved by the European Union and Japanese patent authorities.

• Lundbeck’s Vortioxetine Approved In Canada For Major Depressive Disorder

  10/30/2014

  Lundbeck has just received approval from Health Canada for Trintellix (vortioxetine hydrobromide) for the treatment of major depressive disorder (MDD).

• Vaxart’s Tablet Flu Vaccine Succeeds In Phase 1 Clinical Trial

  10/22/2014

  San Francisco-based biotech Vaxart has announced results from a Phase 1 clinical study of its tablet vaccine candidate for H1N1 seasonal influenza demonstrating that the tablet form was just as effective at providing protective immunity when compared to currently licensed flu injections.

• Personalized Vaccines For Ovarian Cancer To Enter Clinical Trials

  10/21/2014

  University of Connecticut researchers have developed a novel method for making personalized vaccines to treat patients with ovarian cancer.

• Ipsen's Decapeptyl Shows Positive Phase 3 Results For Prostate Cancer

  10/16/2014

  French pharmaceutical company Ipsen has announced positive results from the Phase 3 study of its prostate cancer treatment, Decapeptyl (triptorelin pamoate), with subcutaneous administration of the drug. The results were presented at the European Association of Urology conference in Poland last week.